Woodstock Corp Increases Stock Holdings in OmniAb, Inc. (NASDAQ:OABI)

Woodstock Corp boosted its stake in OmniAb, Inc. (NASDAQ:OABI) by 1.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 802,578 shares of the company’s stock after buying an additional 9,725 shares during the quarter. Woodstock Corp owned approximately 0.57% of OmniAb worth $2,841,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Barclays PLC grew its position in OmniAb by 321.5% in the 3rd quarter. Barclays PLC now owns 143,215 shares of the company’s stock worth $606,000 after purchasing an additional 109,236 shares in the last quarter. State Street Corp boosted its stake in shares of OmniAb by 1.7% in the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after buying an additional 34,654 shares during the last quarter. Murchinson Ltd. bought a new position in shares of OmniAb in the third quarter valued at approximately $4,230,000. PDT Partners LLC purchased a new stake in shares of OmniAb during the third quarter valued at approximately $123,000. Finally, Walleye Capital LLC purchased a new stake in shares of OmniAb during the third quarter valued at approximately $61,000. 72.08% of the stock is owned by hedge funds and other institutional investors.

OmniAb Trading Down 1.9 %

OmniAb stock opened at $3.18 on Friday. The business’s 50 day simple moving average is $3.77 and its 200 day simple moving average is $4.07. OmniAb, Inc. has a 12 month low of $3.16 and a 12 month high of $6.55.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. Benchmark reissued a “buy” rating and issued a $8.00 price target on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.